Details of the Drug

General Information of Drug (ID: DMTY96S)

Drug Name
Eptacog beta
Indication
Disease Entry ICD 11 Status REF
Chronic lymphocytic leukaemia 2A82.0 Phase 1/2 [1]
Mantle cell lymphoma 2A85.5 Phase 1/2 [1]
Non-hodgkin lymphoma 2B33.5 Phase 1/2 [1]
Drug Type
Small molecular drug
Cross-matching ID
TTD ID
DNXH76
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Thioredoxin reductase (PRDX5) TTLPJWH PRDX5_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04419389) APR-246 in Combination With Ibrutinib or Venetoclax-R in Subjects With TP53-Mutant R/R Non Hodgkin Lymphomas (NHL) (R/R). U.S. National Institutes of Health.
2 APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell Death Dis. 2013 Oct 24;4:e881.